BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now
May 28, 2015 at 09:35 AM EDT
In a report published Thursday, BMO Capital analyst Jim Birchenough reiterated an Outperform rating on Five Prime Therapeutics Inc ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.